Minretumomab (CC-49) is a mouse monoclonal antibody targeting TAG-72 (tumour-associated glycoprotein 72), optimised from the B72.3 antibody, and can be used for research into breast cancer, colon cancer, lung cancer, and pancreatic cancer.

Methods:
In this study, subcutaneous, orthotopic, and peritoneal carcinomatosis mouse models were established using the colorectal cancer cell line LS174T. The humanized anti-TAG-72 antibody (Minretumomab) was conjugated with the near-infrared dye IR800CW and administered via tail vein injection. Fluorescence imaging was performed 72 hours after injection.
Results:
In the subcutaneous model, the optimal imaging was achieved with a 50 μg dose of Minretumomab, yielding a tumor-to-liver fluorescence ratio of 7.39. In the orthotopic model, metastatic lesions smaller than 1 mm were clearly detected by fluorescence imaging but were invisible under bright light, demonstrating the probe’s high sensitivity and specificity for tumor imaging.[1]